Colorectal Cancer Market S Expected to Grow During the Forecast Period (2019-2032), DelveInsight | Key Companies – Roche, Eli Lilly, and Others

DelveInsight’s Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Colorectal Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

 

The Colorectal Cancer Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

 

Colorectal Cancer: Overview

Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. It is the third leading cause of death from cancer in the United States. Colorectal cancer is cancer that starts in the colon or the rectum; these cancers can also be named colon cancer or rectal cancer, depending on where they start. Also, most colorectal cancers (CRCs) start as a growth on the inner lining of the colon or rectum; these growths are called polyps.

 

 

Some of the key facts of the Colorectal Cancer Market Report

Colorectal Cancer is most frequently diagnosed among people aged 65–74.
Through secondary research, it can be concluded that mCRC is more common in men as compared to women.
As per the American Institute for Cancer Research, there were over 1.8 million new cases in 2018 worldwide. In 2018, the age-standardized rate of CRC per 100,000 cases were 38.9 in Japan, 33.4 in Spain and 32.1 in the United Kingdom.

 

Colorectal Cancer Market

The Colorectal Cancer Market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Colorectal Cancer Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Colorectal Cancer Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Colorectal Cancer Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

 

Colorectal Cancer Market Insights

The decision to opt for a treatment option for mCRC depends on several factors, including the extent of cancer and its reach to any other organs. While, usually, colon cancer spreads to the liver, It can also spread to the lungs, the lining of the abdomen (peritoneum), the ovaries, the brain, or other organs. Most often, a combination of the therapies are opted for better results.

 

Colorectal Cancer Treatment Market

The treatment options and recommendations of CRC depends on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. The treatment options majorly include surgical resection in the early stages of cancer development followed by effective therapies which includes radiation therapy, targeted therapy, immunotherapy and chemotherapy.

 

Colorectal Cancer Epidemiology

The epidemiology section covers insights into the historical and current Colorectal Cancer Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Colorectal Cancer Drugs & Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer Market or expected to get launched in the market during the study period. The analysis covers Colorectal Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Colorectal Cancer Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

 

Colorectal Cancer Emerging Therapies

Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Pierre Fabre, along with others, there are several emerging key players, which are expected to change the dynamics of the Metastatic Colorectal Cancer (mCRC) market in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage, which includes AB Science (Masitinib), Merck Sharp and Dohme (Vicriviroc), Merck KGaA (Avelumab), Puma Biotechnology (Neratinib), Daiichi Sankyo (U3-1402), G1 therapeutics (Trilaciclib) along with several others that are under clinical development. The launch of these emerging therapies is expected during the forecast period of 2020–2030.

 

Colorectal Cancer Companies

Pfizer/Pierre Fabre
Roche
Taiho Oncology
Eli Lilly
Merck Sharp & Dohme, and others

 

Colorectal Cancer Market Drugs

Keytruda
Cyramza (Ramucirumab)
Trifluridine/tipiracil (Lonsurf)
Capecitabine (Xeloda)
Braftovi (Encorafenib) + Cetuximab, and others

 

Read Full Research Report @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market  

 

Table of content

Key Insights
Executive Summary
Competitive Intelligence Analysis
Market Overview at a Glance
Disease Background and Overview
Patient Journey
Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Colorectal Cancer Market Treatment
Marketed Products
Emerging Therapies
Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

 

Consult with our Business Expert @  https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market  

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/